News | June 10, 2026
GSK bets big on oncology with $10.6 billion Nuvalent acquisition
Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio
Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio
Advanced molecular diagnostics solution enables rapid, high-accuracy biomarker detection for precision oncology
Initiatives at Churchgate Station and Mahindra & Mahindra focus on early detection, public education, and tobacco-related cancer prevention
The conference highlighted research suggesting that deuterium levels may influence key biological processes
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
With standout ADC and t-cell engager response data across hard-to-treat cancers
Access to genomic testing, not therapy cost, is the biggest challenge
Highlighting KEYTRUDA & expanding cancer pipeline
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
